All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry

GGTI-2418

CAS number:501010-06-6    molecular formula:C23H31N5O4

overview

compound introduction

GGTI-2418 is a highly potent, competitive, and selective geranylgeranyltransferase I ( GGTase I ) inhibitor. GGTI-2418 inhibits GGTase I and FTase activities with IC 50 s of 9.5 nM and 53 μM, respectively. GGTI-2418 also increases p27(Kip1) and induces significant regression of breast tumors In Vitro GGTI-2418 inhibits GGTase I and FTase activities with IC 50 s of 9.5±2.0 nM and 53±11 μM, respectively, a 5,600-fold selectivity toward inhibition of GGTase I versus FTase. GGTI-2418 demonstrates competitive inhibition of GGTase I against the H-Ras-CVLL protein with a K i of 4.4±1.6 nM. GGTi-2418 (10-15 μM; 16 hours) treatment delocalizes FBXL2 and stabilizes IP3R3. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: HeLa cells Concentration: 10-15 μM Incubation Time: 16 hours Result: Delocalized FBXL2 and stabilized IP3R3. In Vivo GGTI-2418 (100 mg/kg daily or 200 mg/kg every third day; 15 days) significantly inhibits the growth of breast tumor xenografts in nude mice with MDA-MB-231 xenografts . GGTI-2418 (100 mg/kg daily; 5 days) induces regression of ErbB2-driven mammary tumors in ErbB2 transgenic mice . GGTI-2418 inhibits the geranylgeranylation of Rap1 and causes a dramatic decrease in S473 phosphorylation of Akt. GGTI-2418 also upregulates p27 levels in vivo . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Nude mice implanted with MDA-MB-231 breast cancer tumors Dosage: 100 mg/kg daily or 200 mg/kg every third day Administration: Injected intraperitoneally; 15 days Result: Inhibited the growth of breast tumor xenografts. Animal Model: ErbB2 transgenic mice Dosage: 100 mg/kg/day Administration: Subcutaneously; 5 days Result: Halted tumor growth and induced massive tumor regression. Tumor decreased by 76% following GGTI-2418 treatment. Form:Solid IC50& Target:IC50: 9.5 nM (GGTase I), 53 μM (FTase)

Specs

Chinese alias-
English aliasAKOS040733252 | (S)-2-((S)-2-Benzyl-4-((5-methyl-1H-imidazol-4-yl)methyl)-3-oxopiperazine-1-carboxamido)-4-methylpentanoic acid | M67G28K74K | PTX-100 | 501010-06-6 (free acid) | SCHEMBL19236435 | GGTI 2418 | EX-A3132 | Q27283547 | SCHEMBL16112087 | BVA01
CAS number501010-06-6molecular formulaC23H31N5O4
molecular weight441.5 g/molExact mass≥98%
PSA119.000 Ųlogp2.200

numbering system

No numbering system information yet

physicochemical properties

No physical and chemical property information yet

Safety information

No safety information yet

Production methods and uses

No production method and use information yet

Related

upstream information

No upstream information yet

downstream information

No downstream information yet

MSDS

Found 0 shareMSDS